UroGen Q3 JELMYTO revenue up 41% to $16.1M; net loss narrows to $25.8M

UroGen Pharma Ltd.

JELMYTO net product revenue $16.1M (+41% YoY); operating loss improved to $18.1M from $23.4M.
Net loss $25.8M ($1.13/share) vs $30.2M ($1.35/share) in Q3 2021; cash, cash equivalents and marketable securities $95.9M.
ENVISION Phase 3 trial for UGN-102 enrollment completion expected as soon as end of Nov 2022; NDA submission anticipated H1 2024.
FDA authorized extension of JELMYTO in-use period from 8 to 96 hours following reconstitution.
Appointed Dr. Leana S. Wen and Dan Wildman to the Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UroGen Pharma Ltd. reported the third quarter ended September 30, 2022 results: revenue $16.1 million.

Period: the third quarter ended September 30, 2022
Revenue: $16.1 million
Result: reported results

Exact text from the filing

invasive bladder cancer (LG-IR-NMIBC) expected as soon as the end of November 2022; NDA submission anticipated in first half of 2024 • Reported JELMYTO ® net product revenue of $16.1 million, an increase of 41% from the same period last year • FDA authorized extension of the in-use period for JELMYTO ® admixture from 8 to 96 hours following reconstitution further

View on SEC.gov

Browse all earnings releases →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-22-281988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.